Joycelin Canavan

Radiation oncologist @ClevelandClinic Fairview Hospital #CleClinicCancer #SBRT #GU #GI

[MV Chandrakanth @ChandrakanthMv]

POSEIDON IPD meta-analysis #ASCOGU26
• Adding ADT to salvage RT → No significant OS benefit (HR 0.87)
• PSA ≤0.5? RT alone often enough
• PSA >1.6? Consider long-term ADT
Risk-adapted > Routine ADT
#MVOnco #ProstateCancer #GUOnc

[Yüksel Ürün @DrYukselUrun]

Stereotactic radiation outperforms hippocampal-avoidance whole brain radiation for 5–20 brain metastases. It better reduces symptoms and protects daily function. @JAMA_current @BrighamWomens @AyalAizer @OncoAlert

[Neha Vapiwala @NehaVapiwala]

Yep. Plenty of reasons one might choose surgery over #radiotherapy, but the “can’t have surgery later” fear makes even less sense as an increasing # of effective alternatives emerge. “Losing” an option you don’t need is not a loss. This isn’t a knock on surgery, it’s a win for #prostatecancer patients.

[Dr. Nina Niu Sanford @NiuSanford]

Interpreting liver mets on MRI can be challenging, in part b/c imaging features (hypo vs hypervascularity) vary by primary tumor site.

I adapted this slide from Dr. Jim Apisarnthanarax presentation at ASTRO.

Important for diagnosing & if treating w MR-guided RT.

[Rohit Malde @roxboxfix]

How to decide PMRT in pT3NoMo

Magee Equations score
Clinicopathological factors (tumor size, grade, ER, PR, HER2, and Ki67)

If score <18 no benefit with PMRT
Safely Omit PMRT

If score >18 [ no PMRT group had a higher LRR rate compared to the PMRT group ](11% vs. 2%; P =.01)

[ESTRO @ESTRO_RT]

#ESTRO25 Press release:  Two-Week Radiotherapy Proven as Safe and Effective as Eight-Week Course for #ProstateCancer, After 10-Year Follow-Up in Phase III Trial.
👉 https://t.co/p5p7pIlGVS

[Jame Abraham, MD, FACP @jamecancerdoc]

Excellent review - Management of hepatocellular cancer https://t.co/XpSui6IJvs @JCOOP_ASCO @OncoAlert @RyanNipp @ASCO

[Stephen V Liu, MD @StephenVLiu]

Phase II study @TheLancetOncol for unresectable stage III NSCLC: SBRT to primary then chemoradiation to nodes then durvalumab. 1y PFS 63% does not meet primary endpoint but favorable efficacy & safety vs historic standards. Phase III NRG LU008 underway.

https://t.co/SVeiGIqoIo

[Yüksel Ürün @DrYukselUrun]

☢️💊💉Trimodality therapy offers hope for recurrent T1 bladder cancer after BCG failure!
✅ 3-year freedom from cystectomy: 88%
✅ 3-year OS: 69%
✅Distant metastasis at 3 years: 12%
An alternative to radical cystectomy, but safety monitoring is key.
#BladderCancer #Oncology #PrecisionMedicine @OncoAlert @JCO_ASCO
https://t.co/3T5867qdvE

[NonsparseOncologist @5_utr]

‼️ EUROPA interim

Ph3 RCT 70+ y/o low risk breast cancer -> BCS -> adjuvant endocrine only vs adjuvant APBI only

APBI has better HRQoL than endocrine tx, adj mean difference 6.39 (0.14-12.65)

0 IBTR, LRR, or DM events!!

🤩 #SABCS24

[Michael Chuong @MikeChuongMD]

🔥@NRGonc dose escalated #radonc contouring atlas for inoperable #pancreaticcancer in press!🔥
➡️Step-by-step recs for anatomically derived CTV
➡️Dose escalation strategies suggested
➡️Will be reference for upcoming ph3 NRG GI011 trial that requires CTV

https://t.co/kY9JJbc3K9

[Chirag Shah @CShahMD]

Review on how to use of radiation for treatment of arthritis, was great to work on this with @SprakerMDPhD @drbeckta @jamesbyu Dr. Brower, and Dr. Grew now available in PRO: https://t.co/n8cr4s5CSR

[Peter Mallouk @PeterMallouk]

On happiness…

[Rahul Tendulkar, MD @RTendulkarMD]

Burnout & moral injury in medicine have affected so many health care workers. As a mid-career physician, here’s what I’ve learned to combat it - I hope others find it to be helpful.
In Search of Joy and Meaning in Modern Medicine @JCOOP_ASCO https://t.co/NnR5cSbtPT

[Filippo Alongi @alongi_filippo]

Patients affected by para-aortic disease might have a PFS comparable to pelvic ones; LC is high in both cohorts. Our results also support the use of #SBRT for para-aortic #oligometastases

[ASTRO @ASTRO_org]

A new #RedJournal special issue has published, PENTEC: Pediatric Normal Tissue Effects in the Clinic. This special issue represents years of work researching and writing critical reviews about the treatment of childhood cancers. https://t.co/VNUSDCDWIh

[NRG Oncology @NRGonc]

PRESS RELEASE: NRG Oncology Abstract Considered “Best of ASCO” for 2024 Shows Difference in Outcomes for Node-Negative Versus Node-Positive Pancreatic Cancer Patients when Adding Chemoradiation to Systemic Therapy - Read the release: https://t.co/qHqUtjEQOV

[JeeSuk Chang @changjeesuk1]

Check out our new #Yonsei paper on 5fx ablative RT for primary breast tumors.🇰🇷🇨🇦 Excited for BC Cancer's upcoming SABR-PRIMeR trial led by Andrew Bang.📢More attention should be paid to these breast SABR (-ish) approaches in stage IV BC. https://t.co/SelCtSZbx2

[Memorial Sloan Kettering Radiation Oncology @MSK_RadOnc]

New in @JCO_ASCO: @ASCO @CancerCareMASCC @isooworld multidisciplinary evidence-based recommendations for prevention and management of #osteoradionecrosis (#ORN) of the jaw secondary to head & neck #radiation therapy in patients with cancer. #hncsm #radonc

https://t.co/sPXNjurAHm

[Memorial Sloan Kettering Radiation Oncology @MSK_RadOnc]

New in @IJROBP: Phase II trial shows the rate of implant failure in reconstructed pts with #breastCancer treated with IMRT was similar to, but not improved over, conventional, 3D-conformal #radiation. #bcsm serial MRIs may detect early capsular contracture
https://t.co/r1R9EXLXBo